1️⃣ FDA is moving trials out of batch mode
FDA said on April 28 that it has started real-time clinical trial proof-of-concepts with AstraZeneca and Amgen, with comments open until May 29 and pilot selections due in August.
Why it matters
This moves review from cleaned, batched submissions toward live data access. If it sticks, trial infrastructure becomes a regulatory asset.
Coffee talk
If FDA can watch endpoints live, how much of today’s trial timeline is science and how much is plumbing?
2️⃣ Skinny labels are back in court
The Supreme Court hears Hikma v. Amarin on April 29, testing whether generic makers can face inducement claims even when labels carve out patented uses.
Why it matters
A broad ruling for brands would raise litigation risk around generic entry. A broad ruling for Hikma would make carve-outs harder to attack.
Coffee talk
How many generic launches still work if the press release becomes patent evidence?
3️⃣ Teva pays up for launchable neuroscience
Teva agreed on April 29 to buy Emalex for $700M upfront, plus up to $200M in milestones and royalties, adding ecopipam, an NDA-ready pediatric Tourette drug.
Why it matters
Late-stage neurology assets with orphan angles are still scarce. Specialty pharma is paying for near-term filings, not another platform promise.
Coffee talk
Teva is buying a pediatric sales job before the NDA. Who else is short of launchable neuroscience assets?